Brainsway Ltd. (BWAY)
| Market Cap | 114.62M |
| Revenue (ttm) | 31.51M |
| Net Income (ttm) | -7.08M |
| Shares Out | 17.24M |
| EPS (ttm) | -0.41 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 671 |
| Open | 6.41 |
| Previous Close | 6.50 |
| Day's Range | 6.41 - 6.65 |
| 52-Week Range | 5.03 - 11.77 |
| Beta | 0.68 |
| Analysts | Buy |
| Price Target | 0.10 (-98.5%) |
| Earnings Date | May 11, 2022 |
About BWAY
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company prim...
Financial Performance
In 2021, Brainsway's revenue was $29.66 million, an increase of 34.46% compared to the previous year's $22.06 million. Losses were -$6.46 million, 20.0% more than in 2020.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for BWAY stock is "Buy." The 12-month stock price forecast is 0.1, which is a decrease of -98.50% from the latest price.
News
BrainsWay Reports First Quarter 2022 Financial Results and Operational Highlights
Revenue Growth of 30% Year-over-Year in Q1 2022
BrainsWay Launches #DontMissAnotherMoment Social Media Campaign to Promote Mental Health Awareness Month
BrainsWay will donate $5 per share, $2 per comment, and $1 per like to support the work of Mental Health America BrainsWay will donate $5 per share, $2 per comment, and $1 per like to support the work o...
BrainsWay to Report First Quarter Financial Results on May 11, 2022
BURLINGTON, Mass. and JERUSALEM, April 27, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatmen...
BrainsWay Appoints Dr. Joachim Seidel as Vice President of Corporate Development and Strategy
Dr. Seidel has more than 20 years of experience in the medical device industry Dr. Seidel has more than 20 years of experience in the medical device industry
BrainsWay Reports Fourth Quarter and Full-Year 2021 Financial Results and Operational Highlights
Revenue Growth of 34% in 2021, with Record Quarterly and Annual Revenues
BrainsWay to Present at the 32nd Annual Oppenheimer Healthcare Conference
BURLINGTON, Mass. and JERUSALEM, March 01, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatmen...
BrainsWay to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
BURLINGTON, Mass. and JERUSALEM, Feb. 01, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatment...
BrainsWay Announces Final Local Coverage Determination Issued by Regional Medicare Administrative Contractor Palmetto...
Palmetto GBA Covers Medicare Patients in Seven States Palmetto GBA Covers Medicare Patients in Seven States
BrainsWay Announces Addition of Markus Heilig, M.D., Ph.D., to Scientific Advisory Board
World-Renowned Specialist in Addiction and Anxiety Treatment Joins Premier Group of Researchers and Clinicians Advising Company World-Renowned Specialist in Addiction and Anxiety Treatment Joins Premier...
BrainsWay Announces Multiple Publications of New Real-World OCD Data for its Deep TMS™ System
Positive Data Support the Durability and Cost-Effectiveness of Deep TMS as a Treatment for Obsessive-Compulsive Disorder Positive Data Support the Durability and Cost-Effectiveness of Deep TMS as a Trea...
BrainsWay Announces Publication of Deep TMS™ Trial Results for Reduction of Heavy Drinking in Alcohol-Dependent Subjects
Randomized, Placebo-Controlled, Double-Blind Pilot Study Evaluated Deep TMS Treatment in Reducing Alcohol Consumption and Craving for Adults with Alcohol Use Disorder
BrainsWay Reports Third Quarter 2021 Financial Results and Operational Highlights
Revenue Growth of 34% Year-over-Year in Q3 2021
BrainsWay to Report Third Quarter 2021 Financial Results on November 17, 2021
BURLINGTON, Mass. and JERUSALEM, Nov. 03, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatment...
BrainsWay Announces Data Published in World Psychiatry on Deep Transcranial Magnetic Stimulation (Deep TMS™) for Smok...
Evidence Supports Use of Deep TMS as a Safe and Effective Treatment for Smoking Addiction
BrainsWay to Participate in Two Upcoming Investor Conferences
BURLINGTON, Mass. and JERUSALEM, Sept. 09, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatmen...
BrainsWay to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
BURLINGTON, Mass. and JERUSALEM, Aug. 30, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatment...
BrainsWay Stock Gains On FDA Expanded Use Approval For Its Stimulation Device
The FDA has cleared BrainsWay Ltd's (NASDAQ:BWAY) Deep Transcranial Magnetic Stimulation (Deep TMS) System to reduce comorbid anxiety symptoms in adult patients with depression, also known as anxious de...
FDA Clears BrainsWay Deep TMS™ System for Decreasing Anxiety Symptoms in Depressed Patients
Expanded Depression Indication Further Demonstrates Company's Leadership Position Expanded Depression Indication Further Demonstrates Company's Leadership Position
BrainsWay Hosting Key Opinion Leader Webinar on its Deep TMS™ Therapy for Treating Mental Health Disorders
BURLINGTON, Mass. and JERUSALEM, Aug. 17, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatment...
BrainsWay Reports Second Quarter 2021 Financial Results and Operational Highlights
Strong Revenue Growth of 45% Year-over-Year in Q2 2021
BrainsWay to Report Second Quarter 2021 Financial Results on August 11, 2021
CRESSKILL, N.J. and JERUSALEM, July 28, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments ...
MindPath Care Centers Hosts Open House in Charlotte to Introduce FDA-Cleared Deep TMS™ Treatment for Major Depressive...
Engaging event for local mental health clinicians to learn more about BrainsWay's Deep Transcranial Magnetic Stimulation (Deep TMS) helmet, cleared to treat MDD and OCD, currently available in Charlotte.
BrainsWay to Present at Clinical TMS Society Annual Meeting and Psych Congress Elevate
CRESSKILL, N.J. and JERUSALEM, Israel, June 07, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd . (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation tr...
BrainsWay (BWAY) is in Overbought Territory: What's Next?
BrainsWay (BWAY) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Brainsway Ltd. Sponsored ADR (BWAY) Moves 10.6% Higher: Will This Strength Last?
Brainsway Ltd. Sponsored ADR (BWAY) saw its shares surge in the last session with trading volume being higher than average.